Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients

Inclusion Criteria: * Patients is diagnosed as AML or ALL * Relapse defined as the presence of disease after the achievement of complete remission(CR). Refractory disease is defined as progression from or no response while treated with a previous line chemotherapy regimen, or progression within 30 days of last bone marrow assessment. * Male or female ≥ 18 years of age * Minimal performance status (ECOG 0, ≤2) * Patients must have a measurable disease by bone marrow blast counts of \> 5 % of nucleated cells. * Written informed consent * Adequate hepatic function (LFTs up to X4 the normal limits), renal function calculated Creatinine clearance (CrCl) for Adverse Effects of \>30) * Ability to swallow the medications. * Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation. * Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. Exclusion Criteria: * Active infectious disease uncontrolled by antibiotics. * Partially treated induction patients (i.e. day 14 non responding patients). * Inability to receive high dose salvage chemotherapy. * Patient with known positive HIV serology at screening. * Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study. * Evidence of ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects (CTCAE ) Version 3.0 grade 2. * Pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption. * Mental disorders. * Inability to give written informed consent.